Almost as if to provide a metaphor for HIV treatment strategy - drug combination is the weapon of choice for fighting the infection - two major players said last week they plan to join forces in a $464 million merger whereby Gilead Sciences Inc. will acquire Triangle Pharmaceuticals Inc. (BioWorld Financial Watch)

Having lost its figurative dance partner, Abbott Laboratories Inc., over the summer, Triangle Pharmaceuticals Inc. disclosed that it plans to undergo a "two-step" acquisition by Gilead Sciences Inc. in a deal valued at $464 million. (BioWorld Today)

The field of predictive medicine, one subsector in which the largely faded near-term promise of genomics maintains its color, is just where Myriad Genetics Inc. has wanted to be from the start - but not the only place. (BioWorld Financial Watch)

As Transkaryotic Therapies Inc. revealed a weak hand regarding Replagal (agalsidase alfa), all eyes turned to competitor Genzyme General, which has been playing its cards close to the vest. (Bioworld Today)